Pseudovirus News and Research

RSS

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Researchers look to better understand the molecular basis of E406W-mediated escape from the REGEN-COV cocktail and cilgavimab.

28 Jan 2022

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Researchers show that the CHI3L1 inhibitors reduce epithelial cell infection by SARS-CoV-2 VOC pseudovirus moieties.

27 Jan 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

In a new study, researchers discuss the role of calcium signaling pathways as targets of inhibition in potential new antiviral therapeutic pathways for SARS-CoV-2.

20 Jan 2022

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Researchers have discovered a new way to induce immunity against the RBD.

19 Jan 2022

Three doses Of Pfizer-BioNTech vaccine could offer sufficient level of protection from Omicron

A new study that evaluated the effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the Omicron variant indicates that three doses could offer a sufficient level of protection from disease caused by the Omicron variant.

18 Jan 2022

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

In a new study, researchers analyzed the neutralization of SARS-CoV-2 Omicron and D614G variants before and after subjects received COVID-19 booster vaccinations.

18 Jan 2022

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

A new paper discusses the appearance of quasi-species in a single host with prolonged infection, with different rates of infectivity and sensitivity to neutralization by antibodies elicited by the Pfizer vaccine or those present in convalescent plasma.

17 Jan 2022

Hollow fiber membranes efficiently remove synthetic SARS-CoV-2 from the air

Researchers re-design HFM filters for removing/deactivating viral aerosols.

13 Jan 2022

Cannabinoids may prevent infection with SARS-CoV-2, including variants

A new study published in the Journal of Natural Products of the American Chemical Society and American Society of Pharmacognosy has shown that isolated cannabinoids or those in hemp extracts have the potential to prevent and treat the infection with the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – primarily by blocking viral cell entry.

13 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

Isolated antibodies from BNT162b2 vacinee effective against Omicron variant

Researchers screened BNT162b2 COVID-19 vaccine recipients and cloned broadly neutralizing antibodies from an elite vaccinee.

10 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

A new study aimed to explore whether there is a way to induce the production of potent neutralizing antibodies capable of neutralizing all SARS-CoV-2 variants - including Omicron.

7 Jan 2022

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Researchers investigate SARS-CoV-2 antigenic drift by evaluating the neutralizing activity of sera from patients infected with all five SARS-CoV-2 VOCs.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

The purpose of this study was to determine the breadth of neutralizing activity generated by exposure to certain SARS-CoV-2 variants, vaccinations, or both.

6 Jan 2022

COVID boosters hinder SARS-CoV-2 Omicron

A new preprint research paper reports on the state of current knowledge as to the immune evasion capability of this variant, linking it to the type of vaccine used and the vaccination protocol.

6 Jan 2022

Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations.

5 Jan 2022

Pseudovirus News and Research

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Three doses Of Pfizer-BioNTech vaccine could offer sufficient level of protection from Omicron

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

Hollow fiber membranes efficiently remove synthetic SARS-CoV-2 from the air

Cannabinoids may prevent infection with SARS-CoV-2, including variants

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

Isolated antibodies from BNT162b2 vacinee effective against Omicron variant

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Small molecule identified as a SARS-CoV-2 inhibitor

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

COVID boosters hinder SARS-CoV-2 Omicron

Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News